Cowen and Company restated their outperform rating on shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) in a research report sent to investors on Monday morning. The firm currently has a $165.00 target price on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on GWPH. Maxim Group lowered shares of GW Pharmaceuticals PLC from a buy rating to a hold rating and set a $61.00 target price on the stock. in a report on Tuesday, August 8th. BidaskClub lowered shares of GW Pharmaceuticals PLC from a buy rating to a hold rating in a report on Thursday, August 10th. Leerink Swann restated an outperform rating and issued a $160.00 target price (down previously from $162.00) on shares of GW Pharmaceuticals PLC in a report on Thursday, August 10th. Cantor Fitzgerald set a $208.00 target price on shares of GW Pharmaceuticals PLC and gave the stock a buy rating in a report on Tuesday, August 8th. Finally, Evercore ISI began coverage on shares of GW Pharmaceuticals PLC in a report on Wednesday, August 16th. They issued an outperform rating and a $154.00 target price on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. GW Pharmaceuticals PLC presently has a consensus rating of Buy and an average price target of $149.83.

GW Pharmaceuticals PLC (GWPH) opened at 114.54 on Monday. GW Pharmaceuticals PLC has a 12-month low of $92.65 and a 12-month high of $137.88. The company’s market cap is $2.90 billion. The firm’s 50-day moving average price is $105.92 and its 200-day moving average price is $108.31.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. The business had revenue of $3.14 million during the quarter, compared to analyst estimates of $2.10 million. During the same quarter in the prior year, the company earned ($0.05) EPS. Equities research analysts forecast that GW Pharmaceuticals PLC will post ($5.94) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “GW Pharmaceuticals PLC’s (GWPH) “Outperform” Rating Reaffirmed at Cowen and Company” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.watchlistnews.com/gw-pharmaceuticals-plcs-gwph-outperform-rating-reaffirmed-at-cowen-and-company/1611481.html.

A number of hedge funds have recently modified their holdings of GWPH. Russell Investments Group Ltd. bought a new stake in GW Pharmaceuticals PLC in the 1st quarter worth about $520,000. Wells Fargo & Company MN grew its position in GW Pharmaceuticals PLC by 10.2% in the 1st quarter. Wells Fargo & Company MN now owns 11,462 shares of the biopharmaceutical company’s stock worth $1,386,000 after purchasing an additional 1,063 shares in the last quarter. Karp Capital Management Corp bought a new stake in GW Pharmaceuticals PLC in the 1st quarter worth about $365,000. Ameriprise Financial Inc. bought a new stake in GW Pharmaceuticals PLC in the 1st quarter worth about $230,000. Finally, Parametric Portfolio Associates LLC grew its position in GW Pharmaceuticals PLC by 21.4% in the 1st quarter. Parametric Portfolio Associates LLC now owns 5,132 shares of the biopharmaceutical company’s stock worth $621,000 after purchasing an additional 903 shares in the last quarter. 75.06% of the stock is owned by institutional investors and hedge funds.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.